Cargando…
Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
AIM: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury. BACKGROUND: Hepatic toxicity is the most serious complication in treatment of tuberculosis. METHODS: In a randomized double blind clinical trial (AC...
Autores principales: | Marjani, Majid, Fahim, Fanak, Sadr, Makan, Kazempour Dizaji, Mehdi, Moniri, Afshin, Khabiri, Shadi, Tabarsi, Payam, Velayati, Ali Akbar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536020/ https://www.ncbi.nlm.nih.gov/pubmed/31191838 |
Ejemplares similares
-
Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
por: Marjani, Majid, et al.
Publicado: (2016) -
Etiology of Respiratory Complications among Iranian HIV Infected Patients
por: Marjani, Majid, et al.
Publicado: (2019) -
The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients
por: Tabarsi, Payam, et al.
Publicado: (2014) -
NRITLD Protocol for the Management of Outpatient Cases of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2021) -
Trisomy 21 as a Risk Factor for Severe Illness in COVID-19: Report of two Cases
por: Babamahmoodi, Abdolreza, et al.
Publicado: (2020)